SBI Contra Fund Direct Growth NAV Falls 0.44% to ₹409.45 on 9 September; 5-Year CAGR at 15.49%

Key Takeaways

• SBI Contra Fund Direct Growth recorded an NAV of ₹409.45 on 9 September 2026 after declining 0.44% over the day.
• The fund's one-year return stood at -0.77%, while its three-year CAGR was 10.89% and five-year CAGR was higher at 15.49%.
• Assets under management stood at ₹48,266 crore, with a Direct Growth expense ratio of 0.86%, a ₹500 minimum SIP and ₹5,000 minimum lump-sum investment.
• TREPS and the four largest disclosed equity holdings together accounted for 24.42% of the portfolio.

SBI Contra Fund Direct Growth ended the 9 September 2026 valuation at ₹409.45, declining 0.44% over the day. The latest movement took place against a broader historical record in which the one-year return stood at -0.77%, considerably below the fund's multi-year annualised figures.

The three-year CAGR was 10.89%, while the five-year CAGR reached 15.49%. That leaves the five-year figure 4.60 percentage points above the three-year annualised return. Since each calculation begins from a different NAV and market environment, the difference describes the fund's historical experience across those particular periods rather than a consistent annual progression.

Fund size stood at approximately ₹48,266 crore. The Direct Growth expense ratio was 0.86%. Investors could begin a SIP at ₹500, whereas the minimum one-time investment was ₹5,000. The exit-load schedule was relatively short: applicable redemptions within 30 days attracted 0.25%, falling to 0.10% after 30 days but within 90 days, with no exit load beyond 90 days.

TREPS accounted for 7.11% of the disclosed allocation. Reliance Industries followed at 4.75%, ICICI Bank at 4.55%, HDFC Bank at 4.54% and Biocon at 3.47%. Together, these five entries represented 24.42%. Excluding TREPS, the four named stocks contributed 17.31% of assets, with the two large private-sector banks carrying very similar weights.

Risk statistics included beta of 0.98, standard deviation of 4.06, alpha of 6.34 and a Sharpe ratio of 0.55. The scheme follows a contrarian investment approach, so its portfolio can differ materially from a conventional broad-market allocation. Those risk measures remain historical observations rather than forecasts of subsequent NAV behaviour.